Loading: 100%
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (14 items missing)
No data available for the selected time periods
in million USD FY '12FY '13FY '14FY '15
Revenues
0
0
0
0
Cost of revenues
0
0
0
0
Gross (loss) profit
0
0
0
0
Research and development
4
5
5
5
Selling, general and administrative
3
4
6
7
Sales and Marketing
0
0
0
0
Total operating expenses
7
9
11
12
Operating loss
-7
-9
-11
-12
Other expense, net
0
0
0
0
Loss before income taxes
0
-9
-11
-12
Income taxes
0
0
0
0
Net loss
-7
-9
-11
-12
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Mar 27, 2015 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (28 items missing)
No data available for the selected time periods
in million USD FY '12FY '13FY '14FY '15
Assets
Cash
0
14
5
7
Related party receivables
0
0
0
0
Other non-trade receivables
0
0
0
0
Accounts receivable
0
0
0
0
Inventory
0
0
0
0
Prepaid expenses
0
0
0
0
Other current assets
0
0
0
0
Total current assets
0
14
6
8
Property, plant and equipment, net
0
1
1
1
Total non-current assets
0
1
1
0
Total assets
0
15
7
9
Liabilities and owners' equity
Accounts payable
0 179000
0 244000
0 370000
0 357000
Related party payables
0 0
0 90000
0 16000
0 0
Accrued and other current liabilities
0 232000
0 161000
0 324000
0 297000
Warrant liability
0 0
0 0
0 0
0 0
Total current liabilities
0 411000
0 495000
1 710000
1 654000
Total non-current liabilities
0 0
0 0
0 0
0 0
Total liabilities
0 411000
0 495000
1 710000
1 654000
Commitments and contingencies (Note 11)
0 0
0 0
0 0
0 0
Series B convertible preferred stock
0 0
0 0
0 0
0 0
Common stock
0 0
0 77000
0 79000
0 141000
Additional paid-in capital
0 0
16 16466000
19 19449000
33 32908000
Accumulated deficit
0 0
-2 -1974000
-13 -13035000
-25 -24739000
Harvard Bioscience net investment
0 27000
0 0
0 0
0 0
Accumulated other comprehensive (loss) income
0 0
0 0
0 1000
0 -8000
Total stockholders' equity
0 27000
15 14569000
6 6494000
8 8302000
Total liabilities and stockholders' equity
0 438000
15 15064000
7 7204000
9 8956000
Remarks restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a restated on Mar 30, 2016 n/a restated on Aug 11, 2016 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (23 items missing)
No data available for the selected time periods
in million USD FY '12FY '13FY '14FY '15
Net loss:
-7
-9
-11
-12
Stock-based compensation expense
1
1
3
4
Depreciation
0
0
0
0
Decrease (Increase) in Related Party Receivables
0
0
0
0
Increase in non-trade receivables
0
0
0
0
Increase in accounts receivable
0
0
0
0
Decrease (increase) in inventories
0
0
0
0
(Increase) decrease in prepaid expenses
0
0
0
0
(Decrease) increase in accounts payable
0
0
0
0
Decrease in related party payable
0
0
0
0
(Decrease) increase in accrued and other current liabilities
0
0
0
0
Net cash used in operating activities
-6
-8
-8
-7
Additions to property, plant and equipment
0
0
-1
0
Net cash used in investing activities
0
0
-1
0
Proceeds from funding provided by Harvard Bioscience, Inc.
6
22
0
0
Proceeds from issuance of common stock, net
0
0
0
4
Proceeds from issuance of Series B convertible preferred stock, net
0
0
0
5
Net cash provided by financing activities
6
22
0
10
Effect of exchange rate changes on cash
0
0
0
0
Net (decrease) increase in cash
0
14
-9
2
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Mar 30, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,